Recommendation of the President – Xuriden (uridine triacetate)
On 8 January 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 4/2026 on the validity of granting approval for the reimbursement of the medicinal product Xuriden (uridine triacetate) for the indication of uridine monophosphate synthase deficiency